New research offers early evidence that psychedelics, including psilocybin, could reduce inflammation in humans, building on lab findings that suggest protective effects against neurodegenerative conditions. The study marks one of the first investigations into how these compounds might benefit patients with diseases like Parkinson’s. Findings indicate a possible link between psychedelic compounds and neuroprotective properties, though further research is needed to confirm clinical applications. Scientists emphasize the need for larger trials to explore the potential therapeutic role of these substances in treating brain-related illnesses.
Lab studies have shown that psychedelics like psilocybin can lower inflammation and may be protective for a range of illnesses. Now, researchers are publishing some of the first data in humans that signals this holds potential for patients with neurodegenerative diseases like Parkinson's disease.
